Wall Street analyst estimates for Sotera Health Company (SHC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.92 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.27 | ||
| 2026-08-06 | $0.26 | $0.24 | +8.8% |
| 2026-05-05 | $0.18 | $0.17 | +5.9% |
| 2026-02-24 | $0.26 | $0.24 | +8.3% |
| 2025-11-04 | $0.26 | $0.22 | +18.2% |
| 2025-08-08 | $0.20 | $0.17 | +17.6% |
| 2025-05-01 | $0.14 | $0.12 | +16.7% |
| 2025-02-27 | $0.21 | $0.21 | +0.0% |
Valuation Ratios
| P/E Ratio | 32.36 |
| Price / Book | 7.96 |
| EV / EBITDA | 13.35 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $746.1M | $778.3M | $818.2M | $931.5M | $1.00B | $1.05B | $1.10B | $1.16B |
| Cost of Revenue | $388.9M | $382.9M | $374.6M | $412.8M | $446.7M | $472.1M | $498.1M | $518.1M |
| Gross Profit | $357.3M | $395.4M | $443.6M | $518.7M | $557.0M | $577.2M | $602.3M | $645.5M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $133.4M | $147.5M | $178.5M | $198.2M | $245.7M | $236.7M | $242.6M | $252.8M |
| Operating Expenses | $191.3M | $211.8M | $237.6M | $261.9M | $308.7M | $300.5M | $304.7M | $252.8M |
| Operating Income | $80.8M | $183.6M | $206.0M | $256.7M | $248.3M | $276.7M | $297.6M | $392.8M |
| EBITDA | $314.4M | $303.5M | $320.0M | $400.8M | -$17.4M | $406.8M | $442.2M | $442.3M |
| Interest Expense | $143.3M | $157.7M | $215.3M | $74.2M | $80.1M | $142.9M | $164.7M | $155.7M |
| Pre-tax Income | $24.2M | -$916,000 | -$38.9M | $175.7M | -$243.1M | $106.0M | $113.9M | $147.5M |
| Income Tax | $30.1M | $19.5M | -$1.4M | $58.6M | -$9.5M | $54.7M | $69.5M | $69.6M |
| Net Income | -$5.9M | -$20.9M | -$38.6M | $116.9M | -$233.6M | $51.4M | $44.4M | $77.9M |
| EPS | $-0.02 | $-0.07 | $-0.14 | $0.41 | $-0.83 | $0.18 | $0.16 | $0.27 |
| EPS (Diluted) | $-0.02 | $-0.07 | $-0.14 | $0.41 | $-0.83 | $0.18 | $0.16 | $0.27 |
| Shares Outstanding (Diluted) | $246.2M | $284.4M | $283.2M | $279.4M | $280.1M | $283.2M | $284.9M | $286.4M |
Price
| Price | $18.55 |
| Market Cap | $5.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALKS · BLCO · GKOS · MMSI · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of SHC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks